In-Depth Examination Of 4 Analyst Recommendations For Staar Surgical
Portfolio Pulse from Benzinga Insights
Staar Surgical (NASDAQ:STAA) has been evaluated by 4 analysts over the last three months, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $44.5, reflecting a 4.71% increase from the previous $42.50. Analyst actions include maintaining, raising, and lowering ratings and price targets. Staar Surgical, a manufacturer of implantable lenses, has shown solid revenue growth of 19.09% as of December 31, 2023, with a net margin of 10.17% and exceptional ROE and ROA, indicating strong financial health.
April 04, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Staar Surgical has received mixed analyst ratings but shows strong financial health with significant revenue growth and profitability. The average 12-month price target has increased, indicating positive sentiment.
The increase in the average 12-month price target and the company's strong financial performance, including a notable revenue growth rate and high profitability metrics, suggest a positive short-term impact on STAA's stock price. Analyst ratings, despite being mixed, lean towards bullish, which could further bolster investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100